Growth Metrics

Innoviva (INVA) Income from Non-Controlling Interests (2017 - 2022)

Innoviva posted quarterly Income from Non-Controlling Interests of -$36.2 million for Q3 2022, down 219.76% year-on-year from $30.2 million in Q3 2021, and down 277.06% on a QoQ basis from $20.4 million in Q2 2022.

Innoviva (INVA) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$36.2 million in Q3 2022.

  • For the quarter ending Q3 2022, Income from Non-Controlling Interests fell 219.76% year-over-year to -$36.2 million; the trailing twelve-month figure through Sep 2023 stood at -$36.2 million (down 198.98% YoY), and the FY2022 full-year result was $6.3 million, down 93.84% from the prior year.
  • Income from Non-Controlling Interests for Q3 2022 stood at -$36.2 million, down from $20.4 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $30.2 million in Q3 2021 and bottomed at -$36.2 million in Q3 2022.
  • The 5-year median for Income from Non-Controlling Interests is $12.7 million (2019), against an average of $10.5 million.
  • The widest annual swing landed in 2018, when Income from Non-Controlling Interests jumped 4128.68%; it then tumbled 219.76% in 2022.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at $5.5 million in 2018, then soared by 118.39% to $11.9 million in 2019, then soared by 77.23% to $21.1 million in 2020, then jumped by 43.08% to $30.2 million in 2021, then sank by 219.76% to -$36.2 million in 2022.
  • The last three Income from Non-Controlling Interests figures came in at -$36.2 million (Q3 2022), $20.4 million (Q2 2022), and $22.1 million (Q1 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -13.75 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2022 -36.18 Mn
Jun 30, 2022 20.43 Mn
Mar 31, 2022 22.09 Mn
Sep 30, 2021 30.21 Mn
Jun 30, 2021 21.90 Mn
Mar 31, 2021 15.57 Mn
Dec 31, 2020 21.11 Mn
Sep 30, 2020 13.40 Mn
Jun 30, 2020 21.38 Mn
Mar 31, 2020 13.52 Mn
Dec 31, 2019 11.91 Mn
Sep 30, 2019 7.24 Mn
Jun 30, 2019 8.32 Mn
Mar 31, 2019 6.23 Mn
Dec 31, 2018 5.46 Mn
Sep 30, 2018 3.08 Mn
Jun 30, 2018 1.99 Mn
Mar 31, 2018 749,000.00
Dec 31, 2017 129,000.00